Tuesday, 28 April 2026
  
Login

Australia's most trusted
source of pharma news

Tuesday, 28 April 2026
News

Big Pharma goes under the hammer

Posted 28 April 2026 PM

Indian generics company Sun Pharma has dropped $16.36 billion (US$11.75 billion) in cash to acquire Organon, offering shareholders more than double what their shares were worth earlier this month in a bid to muscle its way into the upper ranks of the pharma industry.

The offer of US$14 a share is a 103 per cent premium over Organon's closing share price on 9 April, and will be paid by cash Sun has on hand and committed financing from banks. It's been approved by both boards of directors, and with regulatory approvals and acceptance by Organon shareholders is expected to close in early 2027.

To see the whole article, please login

Popular

MD's message to Dept workers
Long-timers jumping companies
Aussie pharma naughty or nice?
PBAC pushes biologics to first line
Latest Jobs
MORE NEWS
Email this article to a friend
From:

 
 
  
Print this article

Copyright Notice

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.

Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.

Welcome to Pharma in Focus

Please log in to read.

Hi

Our old access system is being retired.

Please create a password and click 'Log in' for ongoing access.

Hi

Please choose a password to secure your access to Pharma in Focus (minimum 8 characters).

Hi

You're here because you requested to reset your password.

Please choose a new password (minimum 8 characters).

To search the News Archive you need to be logged in.

 

You can choose not to do this now but after November 30, a password will be required.

To learn more about the new-look Pharma in Focus click here.


Subscribe
 
© 2003 - 2026 Lush Media | Privacy Statement | Subscribe to Pharma in Focus
home